复方鳖甲软肝片联合拉米夫定在肺结核伴慢性乙肝患者中的应用

Application of Compound Biejia Soft Liver Tablet Combined with Lamivudine in Patients with Tuberculosis and Chronic Hepatitis B

目的:讨论复方鳖甲软肝片联合拉米夫定对肺结核伴慢性乙肝患者肝纤维化的影响。方法:选取2017年9月至2019年7月在我中心接受治疗的肺结核伴慢性乙肝患者71例,将其按随机数字表法分为观察组35例,对照组36例。对照组服用常规抗结核、保肝方案及复方鳖甲软肝片治疗,观察组在此基础上增加拉米夫定治疗,对比两组疗效、肝纤维化指标及不良反应。结果:相比对照组,观察组总有效率较高,ALT、AST、TBIL水平及总不良反应发生率较低(P<0.05)。结论:复方鳖甲软肝片联合拉米夫定可有效降低肺结核伴慢性乙肝患者肝纤维化水平,可有效预防肝功能损伤,且不良反应较少,安全性更高。

Objective:To discuss the effect of Compound Biejia Ruangan Tablet Combined with lamivudine on liver fibrosis in patients with pulmonary tuberculosis and chronic hepatitis B.Methods:71 tuberculosis patients with chronic hepatitis B who were treated in our center from September 2017 to July 2019 were divided into observation group(35 cases)and control group(36 cases).The control group was treated with routine antituberculosis,liver protection and Compound Biejia Ruan Gan Pian,and the observation group was treated with lamivudine on this basis,and the curative effect,liver fibrosis index and adverse reactions were compared between the two groups.Results:Compared with the control group,the total effective rate of the observation group was higher,the ALT,AST,TBIL levels and the incidence of total adverse reactions were lower(P<0.05).Conclusion:Compound Biejia Ruangan Tablet Combined with lamivudine can effectively reduce the level of liver fibrosis in patients with pulmonary tuberculosis and chronic hepatitis B,and can effectively prevent liver function damage,with fewer adverse reactions and higher safety.